Longitudinal Assessment of Preterm Infants Treated with Erythropoiesis Stimulating Agents.

IF 1.3 Q3 PEDIATRICS

Current Pediatric Reviews Pub Date : 2023-01-01 DOI:10.2174/1573396319666221219114704

Robin K Ohls, Jean Lowe, Ronald A Yeo, Shrena Patel, Sarah Winter, Richard A Campbell, Shawna Baker, John Phillips

{"title":"Longitudinal Assessment of Preterm Infants Treated with Erythropoiesis Stimulating Agents.","authors":"Robin K Ohls, Jean Lowe, Ronald A Yeo, Shrena Patel, Sarah Winter, Richard A Campbell, Shawna Baker, John Phillips","doi":"10.2174/1573396319666221219114704","DOIUrl":null,"url":null,"abstract":"Objective: We previously reported improved neurodevelopment at 2 and 4 years among preterm infants treated with erythropoietin or darbepoetin, known as erythropoiesis-stimulating agents (ESAs). We now characterize longitudinal outcomes through 6 years.Methods: Children randomized to ESAs or placebo were evaluated at 6 years. Healthy-term children served as controls. Tests of cognition and executive function (EF) were performed.Results: Cognitive/EF scores remained similar between 4 and 6 years within each group (ESA: 43 children; placebo: 17 children; term: 21 children). ESA recipients scored higher than placebo on Full-Scale IQ (94.2 ± 18.6 vs. 81.6 ± 16.7, p = 0.022), and Performance IQ (97.3 ± 16.2 vs. 81.7 ± 15.2, = 0.005). Aggregate EF trended better for the ESA group. Term controls scored better than placebo on all measures. ESA and term controls scored similarly on cognitive and EF tests.Conclusion: ESA recipients had better outcomes than placebo recipients, and were similar to term children. ESAs may improve long-term cognition and executive function in preterm infants.","PeriodicalId":11175,"journal":{"name":"Current Pediatric Reviews","volume":"19 4","pages":"417-424"},"PeriodicalIF":1.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pediatric Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573396319666221219114704","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: We previously reported improved neurodevelopment at 2 and 4 years among preterm infants treated with erythropoietin or darbepoetin, known as erythropoiesis-stimulating agents (ESAs). We now characterize longitudinal outcomes through 6 years.

Methods: Children randomized to ESAs or placebo were evaluated at 6 years. Healthy-term children served as controls. Tests of cognition and executive function (EF) were performed.

Results: Cognitive/EF scores remained similar between 4 and 6 years within each group (ESA: 43 children; placebo: 17 children; term: 21 children). ESA recipients scored higher than placebo on Full-Scale IQ (94.2 ± 18.6 vs. 81.6 ± 16.7, p = 0.022), and Performance IQ (97.3 ± 16.2 vs. 81.7 ± 15.2, = 0.005). Aggregate EF trended better for the ESA group. Term controls scored better than placebo on all measures. ESA and term controls scored similarly on cognitive and EF tests.

Conclusion: ESA recipients had better outcomes than placebo recipients, and were similar to term children. ESAs may improve long-term cognition and executive function in preterm infants.

查看原文本刊更多论文

用促红细胞生成剂治疗早产儿的纵向评价。

目的:我们之前报道过2岁和4岁早产儿接受促红细胞生成素或达贝生成素(即促红细胞生成素促红细胞生成素)治疗后神经发育得到改善。我们现在描述了6年的纵向结果。方法:随机分配到esa或安慰剂组的儿童在6岁时进行评估。健康足月儿童作为对照组。进行认知和执行功能(EF)测试。结果:认知/EF得分在各组4至6岁之间保持相似(ESA: 43名儿童;安慰剂组:17例;学期:21个孩子)。ESA接受者在全面智商(94.2±18.6 vs. 81.6±16.7,p = 0.022)和绩效智商(97.3±16.2 vs. 81.7±15.2，= 0.005)上的得分高于安慰剂。ESA组的总EF趋势更好。长期控制组在所有指标上的得分都高于安慰剂组。ESA和term control在认知和EF测试中的得分相似。结论:ESA接受者的预后优于安慰剂接受者，并且与足月儿童相似。esa可改善早产儿的长期认知和执行功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Pediatric Reviews PEDIATRICS-

CiteScore

4.30

自引率

0.00%

发文量

期刊介绍： Current Pediatric Reviews publishes frontier reviews on all the latest advances in pediatric medicine. The journal’s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in pediatric medicine.